- Home
- NMRA vs CDXS Comparison
NMRA vs CDXS Comparison
Compare NMRA & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | CDXS |
|---|---|---|
| Founded | 2019 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Major Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.0M | 256.3M |
| IPO Year | 2023 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NMRA | CDXS |
|---|---|---|
| Price | $0.74 | $1.40 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 932.8K | 809.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.23 | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $0.73 | $0.96 |
| 52 Week High | $3.65 | $2.98 |
Technical Indicators
Market Signals| Indicator | NMRA | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 16.66 | 37.18 |
| Support Level | N/A | $1.22 |
| Resistance Level | $1.74 | $1.76 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 0.11 | 20.22 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.